

Jignesh K Patel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7477059/publications.pdf>

Version: 2024-02-01

98
papers

5,221
citations

172457

29
h-index

88630

70
g-index

99
all docs

99
docs citations

99
times ranked

4947
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantitative Assessment of Cardiac Hypermetabolism and Perfusion for Diagnosis of Cardiac Sarcoidosis. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 86-96.	2.1	20
2	Post-transplantation outcomes of sensitized patients receiving durable mechanical circulatory support. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 365-372.	0.6	4
3	Heterogeneity of liver fibrosis in patients with congestive hepatopathy: A biopsy and explant comparison series. <i>Annals of Diagnostic Pathology</i> , 2022, 56, 151876.	1.3	6
4	The impact of induction therapy on mortality and treated rejection in cardiac transplantation: A retrospective study. <i>Journal of Heart and Lung Transplantation</i> , 2022, , .	0.6	5
5	Long-term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A single-center experience. <i>Clinical Transplantation</i> , 2022, , e14591.	1.6	2
6	Cardiac Amyloidosis Treatment. <i>Methodist DeBakey Cardiovascular Journal</i> , 2022, 18, 59-72.	1.0	18
7	High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning. <i>JAMA Cardiology</i> , 2022, 7, 386.	6.1	63
8	Heart transplantation in muscular dystrophy: Single-center analysis. <i>Clinical Transplantation</i> , 2022, , e14645.	1.6	0
9	Cardiac microstructural alterations in immune-inflammatory myocardial disease: a retrospective case-control study. <i>Cardiovascular Ultrasound</i> , 2022, 20, 9.	1.6	0
10	HLA Homozygosity and Likelihood of Sensitization in Kidney Transplant Candidates. <i>Transplantation Direct</i> , 2022, 8, e1312.	1.6	2
11	Prognostic Value of Increased Mitral Valve Gradient After Transcatheter Edge-to-Edge Repair for Primary Mitral Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 935-945.	2.9	25
12	Induction Therapy and Therapeutic Antibodies. <i>Handbook of Experimental Pharmacology</i> , 2022, , .	1.8	0
13	Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1210-1213.	0.6	12
14	Seeing Old Landscapes With New Eyes: A Voyage Into the Endomyocardial Biopsy to Improve Risk Stratification After Heart Transplant Using Computational Analysis. <i>Circulation</i> , 2022, 145, 1578-1580.	1.6	1
15	Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1417-1425.	0.6	10
16	Stem cell donor HLA typing improves CPRA in kidney allocation. <i>American Journal of Transplantation</i> , 2021, 21, 138-147.	4.7	13
17	Statistical performance of 16 posttransplant risk scores in a contemporary cohort of heart transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 645-656.	4.7	8
18	Outcomes of Heart Transplantation in Cardiac Amyloidosis Patients: A Single Center Experience. <i>Transplantation Proceedings</i> , 2021, 53, 329-334.	0.6	13

#	ARTICLE	IF	CITATIONS
19	Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients. American Journal of Transplantation, 2021, 21, 2479-2488.	4.7	41
20	Heart Transplant Immunosuppression Strategies at Cedars-Sinai Medical Center. International Journal of Heart Failure, 2021, 3, 15.	2.7	15
21	Clinical Utility of SPECT in the Heart Transplant Population. Transplantation, 2021, Publish Ahead of Print, .	1.0	4
22	Intermediate-term outcomes of heart transplantation for cardiac amyloidosis in the current era. Clinical Transplantation, 2021, 35, e14308.	1.6	10
23	The challenge of heart transplantation in sensitized patients-carfilzomib and the importance of shared experience. Journal of Heart and Lung Transplantation, 2021, 40, 604-606.	0.6	0
24	Diagnostic Accuracy of Cardiovascular Magnetic Resonance for Cardiac Transplant Rejection. JACC: Cardiovascular Imaging, 2021, 14, 2337-2349.	5.3	10
25	Heart transplant in Jehovah's Witness patients: A case-control study. Journal of Heart and Lung Transplantation, 2021, 40, 575-579.	0.6	3
26	Recipient and surgical factors trigger severe primary graft dysfunction after heart transplant. Journal of Heart and Lung Transplantation, 2021, 40, 970-980.	0.6	18
27	The effects of donor-specific antibody characteristics on cardiac allograft vasculopathy. Clinical Transplantation, 2021, 35, e14483.	1.6	7
28	Advanced heart failure and heart transplantation in adult congenital heart disease in the current era. Clinical Transplantation, 2021, 35, e14451.	1.6	0
29	Eculizumab for antibody-mediated rejection in heart transplantation: A case-control study. Clinical Transplantation, 2021, , e14454.	1.6	4
30	Plasma kallikrein predicts primary graft dysfunction after heart transplant. Journal of Heart and Lung Transplantation, 2021, 40, 1199-1211.	0.6	11
31	Development and validation of specific post-transplant risk scores according to the circulatory support status at transplant: A UNOS cohort analysis. Journal of Heart and Lung Transplantation, 2021, 40, 1235-1246.	0.6	4
32	Crossing low/moderate-level donor-specific antibodies during heart transplantation. Clinical Transplantation, 2021, 35, e14196.	1.6	5
33	Simultaneous Tc-99m PYP/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis. Journal of Nuclear Cardiology, 2020, 27, 28-37.	2.1	25
34	Comparative Prognostic and Diagnostic Value of Myocardial Blood Flow and Myocardial Flow Reserve After Cardiac Transplantation. Journal of Nuclear Medicine, 2020, 61, 249-255.	5.0	28
35	Recent advances in the role of mammalian target of rapamycin inhibitors on cardiac allograft vasculopathy. Clinical Transplantation, 2020, 34, e13769.	1.6	9
36	Coronary computed tomography-angiography quantitative plaque analysis improves detection of early cardiac allograft vasculopathy: A pilot study. American Journal of Transplantation, 2020, 20, 1375-1383.	4.7	13

#	ARTICLE	IF	CITATIONS
37	HLA-DQ mismatches stimulate de novo donor specific antibodies in heart transplant recipients. Human Immunology, 2020, 81, 330-336.	2.4	21
38	Association of vimentin antibody and other non-HLA antibodies with treated antibody mediated rejection in heart transplant recipients. Human Immunology, 2020, 81, 671-674.	2.4	10
39	The rising scourge of acute renal injury after heart transplantation. Transplant International, 2020, 33, 1643-1644.	1.6	1
40	Response by Coutance et al to Letter Regarding Article, "Identification and Characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation: A Population-Based Study". Circulation, 2020, 142, e409-e410.	1.6	0
41	Donor organ evaluation in the era of coronavirus disease 2019: A case of nosocomial infection. Journal of Heart and Lung Transplantation, 2020, 39, 611-612.	0.6	5
42	Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. Transplantation Proceedings, 2020, 52, 2711-2714.	0.6	33
43	cBIN1 Score (CS) Identifies Ambulatory HFREF Patients and Predicts Cardiovascular Events. Frontiers in Physiology, 2020, 11, 503.	2.8	7
44	Blood-based immunological monitoring after heart transplant. Current status and future prospects. Indian Journal of Thoracic and Cardiovascular Surgery, 2020, 36, 194-199.	0.6	2
45	Left ventricular assist systems and strokes: Statins to the rescue?. Journal of Heart and Lung Transplantation, 2020, 39, 593-594.	0.6	0
46	Evaluation for Heart Transplantation and LVAD Implantation. Journal of the American College of Cardiology, 2020, 75, 1471-1487.	2.8	77
47	JC virus-associated nephropathy in a post-heart and kidney transplantation patient. Transplant Infectious Disease, 2020, 22, e13288.	1.7	7
48	Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. Journal of the American College of Cardiology, 2019, 74, 285-295.	2.8	170
49	Mechanical circulatory support for cardiac amyloidosis. Clinical Transplantation, 2019, 33, e13663.	1.6	22
50	Quantitative myocardial tissue characterization by cardiac magnetic resonance in heart transplant patients with suspected cardiac rejection. Clinical Transplantation, 2019, 33, e13704.	1.6	9
51	Desensitization in heart transplant recipients: Who, when, and how. Clinical Transplantation, 2019, 33, e13639.	1.6	6
52	Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: A prospective multicenter study. American Journal of Transplantation, 2019, 19, 2889-2899.	4.7	138
53	Combined Heart and Kidney Transplantation: Clinical Experience in 100 Consecutive Patients. Journal of the American Heart Association, 2019, 8, e010570.	3.7	33
54	Amyloid and the Heart. Current Cardiology Reports, 2019, 21, 164.	2.9	6

#	ARTICLE	IF	CITATIONS
55	Cerebral Amyloid Angiopathy-Related Inflammation in the Immunosuppressed: A Case Report. <i>Frontiers in Neurology</i> , 2019, 10, 1283.	2.4	8
56	Predicted heart mass is the optimal metric for size match in heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 156-165.	0.6	138
57	The management of antibodies in heart transplantation: An ISHLT consensus document. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 537-547.	0.6	114
58	Peri-operative desensitization—A promising strategy for overcoming the antibody barrier in heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 577-578.	0.6	0
59	Diagnosis and Management of Chagas Cardiomyopathy in the United States. <i>Current Cardiology Reports</i> , 2018, 20, 131.	2.9	13
60	Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization. <i>JAMA Cardiology</i> , 2018, 3, 1206.	6.1	35
61	Neurological Prognostication of Cardiac Arrest in an Era of Extracorporeal Membrane Oxygenation. <i>Neurohospitalist</i> , The, 2017, 7, 35-38.	0.8	1
62	Corticosteroid wean after heart transplantation—Is there a risk for antibody formation?. <i>Clinical Transplantation</i> , 2017, 31, e12916.	1.6	6
63	Prioritization for sensitization in heart transplantation—An approach toward greater equity. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 486-487.	0.6	1
64	Calculated panel-reactive antibody predicts outcomes on the heart transplant waiting list. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 787-796.	0.6	71
65	The β_1 -Adrenergic Receptor IgG Subclass 3 Autoantibody in Dilated Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2017, 69, 978-980.	2.8	5
66	The Sensitized Patient Awaiting Heart Transplantation. , 2017, , 57-71.		0
67	Induction Therapy With Antithymocyte Globulin in Patients Undergoing Cardiac Transplantation Is Associated With Decreased Coronary Plaque Progression as Assessed by Intravascular Ultrasound. <i>Circulation: Heart Failure</i> , 2016, 9, e002252.	3.9	32
68	Early Denervation and Later Reinnervation of the Heart Following Cardiac Transplantation: A Review. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	83
69	Desensitization strategies in adult heart transplantation—Will persistence pay off?. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 962-972.	0.6	56
70	Elevated immune monitoring as measured by increased adenosine triphosphate production in activated lymphocytes is associated with accelerated development of cardiac allograft vasculopathy after cardiac transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1018-1023.	0.6	5
71	Early and late AMR in heart transplantation—Distinct entities?. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1055-1056.	0.6	1
72	Pathology of Chronic Chagas Cardiomyopathy in the United States. <i>American Journal of Clinical Pathology</i> , 2016, 146, 191-198.	0.7	17

#	ARTICLE	IF	CITATIONS
73	Optimizing transplantation of sensitized heart candidates using 4 antibody detection assays to prioritize the assignment of unacceptable antigens. Journal of Heart and Lung Transplantation, 2016, 35, 165-172.	0.6	47
74	B cells in transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 704-710.	0.6	29
75	Risk of deep vein thrombosis and pulmonary embolism after heart transplantation: clinical outcomes comparing upper extremity deep vein thrombosis and lower extremity deep vein thrombosis. Clinical Transplantation, 2015, 29, 629-635.	1.6	22
76	Extracorporeal photopheresis in heart transplant rejection. Transfusion and Apheresis Science, 2015, 52, 167-170.	1.0	17
77	Elevated immune monitoring early after cardiac transplantation is associated with increased plaque progression by intravascular ultrasound. Clinical Transplantation, 2015, 29, 103-109.	1.6	5
78	Vitamin therapy after heart transplantation. Expert Review of Cardiovascular Therapy, 2015, 13, 1071-1074.	1.5	5
79	Response. Transplantation Proceedings, 2015, 47, 2077.	0.6	0
80	Randomized Pilot Trial of Gene Expression Profiling Versus Heart Biopsy in the First Year After Heart Transplant. Circulation: Heart Failure, 2015, 8, 557-564.	3.9	74
81	Approach to the Sensitized Patient Awaiting Heart Transplantation. Current Transplantation Reports, 2014, 1, 290-299.	2.0	0
82	Report from a consensus conference on primary graft dysfunction after cardiac transplantation. Journal of Heart and Lung Transplantation, 2014, 33, 327-340.	0.6	523
83	Increased Negative Impact of Donor HLA-Specific Together With Non-HLA-Specific Antibodies on Graft Outcome. Transplantation, 2014, 97, 595-601.	1.0	105
84	The impact of mean first-year heart rate on outcomes after heart transplantation: does it make a difference?. Clinical Transplantation, 2013, 27, 659-665.	1.6	10
85	Thoracic Organ Transplantation: Laboratory Methods. Methods in Molecular Biology, 2013, 1034, 127-143.	0.9	9
86	Improving survival during heart transplantation: diagnosis of antibody-mediated rejection and techniques for the prevention of graft injury. Future Cardiology, 2012, 8, 623-635.	1.2	14
87	Cardiac allograft rejection. Journal of the Royal College of Surgeons of Edinburgh, 2011, 9, 160-167.	1.8	84
88	Report from a consensus conference on antibody-mediated rejection in heart transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 252-269.	0.6	328
89	Heart transplant recipients supported with extracorporeal membrane oxygenation: Outcomes from a single-center experience. Journal of Heart and Lung Transplantation, 2011, 30, 1250-1256.	0.6	82
90	Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 1320-1326.	0.6	145

#	ARTICLE	IF	CITATIONS
91	HLA and MICA: Targets of Antibody-Mediated Rejection in Heart Transplantation. Transplantation, 2011, 91, 1153-1158.	1.0	99
92	The long-term outcome of treated sensitized patients who undergo heart transplantation. Clinical Transplantation, 2011, 25, E61-E67.	1.6	91
93	Quest for lower immunosuppression in cardiac transplantation: an analysis of the TICTAC trial. Future Cardiology, 2011, 7, 293-297.	1.2	1
94	Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. Journal of Heart and Lung Transplantation, 2010, 29, 504-508.	0.6	91
95	The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. Journal of Heart and Lung Transplantation, 2010, 29, 914-956.	0.6	1,385
96	Report From a Consensus Conference on the Sensitized Patient Awaiting Heart Transplantation. Journal of Heart and Lung Transplantation, 2009, 28, 213-225.	0.6	158
97	Asymptomatic Antibody-mediated Rejection After Heart Transplantation Predicts Poor Outcomes. Journal of Heart and Lung Transplantation, 2009, 28, 417-422.	0.6	190
98	Ten-Year Follow-Up of a Randomized Trial of Pravastatin in Heart Transplant Patients. Journal of Heart and Lung Transplantation, 2005, 24, 1736-1740.	0.6	165